BCDA - BioCardia files for $50M mixed shelf
2023-10-20 12:43:32 ET
More on BioCardia
- BioCardia doesn't see Phase 3 study meeting primary endpoint, stock slides
- BioCardia plummets 47% on phase 3 enrollment pause for heart failure therapy
- Seeking Alpha’s Quant Rating on BioCardia
- Historical earnings data for BioCardia
For further details see:
BioCardia files for $50M mixed shelf